Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: April 22, 2022
Atherosclerosis
is
a
chronic
inflammatory
vascular
disease
driven
by
traditional
and
nontraditional
risk
factors.
Genome-wide
association
combined
with
clonal
lineage
tracing
clinical
trials
have
demonstrated
that
innate
adaptive
immune
responses
can
promote
or
quell
atherosclerosis.
Several
signaling
pathways,
are
associated
the
response,
been
implicated
within
atherosclerosis
such
as
NLRP3
inflammasome,
toll-like
receptors,
proprotein
convertase
subtilisin/kexin
type
9,
Notch
Wnt
which
of
importance
for
development
regression.
Targeting
especially
inflammasome
pathway
its
regulated
cytokine
interleukin-1β,
could
represent
an
attractive
new
route
treatment
atherosclerotic
diseases.
Herein,
we
summarize
knowledge
on
cellular
participants
key
pathways
in
atherosclerosis,
discuss
preclinical
studies
targeting
these
going
to
target
some
processes,
effects
quelling
inflammation
clinic.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: July 12, 2023
Abstract
Studies
in
neurodegenerative
diseases,
including
Alzheimer’s
disease,
Parkinson’s
disease
and
Amyotrophic
lateral
sclerosis,
Huntington’s
so
on,
have
suggested
that
inflammation
is
not
only
a
result
of
neurodegeneration
but
also
crucial
player
this
process.
Protein
aggregates
which
are
very
common
pathological
phenomenon
can
induce
neuroinflammation
further
aggravates
protein
aggregation
neurodegeneration.
Actually,
even
happens
earlier
than
aggregation.
Neuroinflammation
induced
by
genetic
variations
CNS
cells
or
peripheral
immune
may
deposition
some
susceptible
population.
Numerous
signaling
pathways
range
been
to
be
involved
the
pathogenesis
neurodegeneration,
although
they
still
far
from
being
completely
understood.
Due
limited
success
traditional
treatment
methods,
blocking
enhancing
inflammatory
considered
promising
strategies
for
therapy
many
them
got
exciting
results
animal
models
clinical
trials.
Some
them,
few,
approved
FDA
usage.
Here
we
comprehensively
review
factors
affecting
major
pathogenicity
sclerosis.
We
summarize
current
strategies,
both
clinic,
diseases.
Frontiers in Immunology,
Journal Year:
2020,
Volume and Issue:
11
Published: June 23, 2020
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
is
a
member
of
the
genus
Betacoronavirus
within
family
Coronaviridae.
It
an
enveloped
single-stranded
positive-sense
RNA
virus.
Since
December
2019,
global
expansion
infection
has
occurred
with
widespread
dissemination
disease
2019
(COVID-19).
COVID-19
often
manifests
as
only
mild
cold-like
symptomatology,
but
severe
complications
occurs
in
15%
cases.
Respiratory
failure
that
can
be
accompanied
by
systemic
inflammatory
reaction
characterized
cytokine
release.
In
cases,
fatality
caused
rapid
development
lung
injury
characteristic
distress
(ARDS).
Although
ARDS
complication
SARS-CoV-2
infection,
it
not
viral
replication
or
causes
tissue
injury;
rather,
result
dysregulated
hyperinflammation
response
to
infection.
This
pathology
intense,
stimulation
innate
immune
triggers
activation
Nod-like
receptor
family,
pyrin
domain-containing
3
(NLRP3)
inflammasome
pathway
and
release
its
products
including
proinflammatory
cytokines
IL-6
IL-1β.
Here
we
review
literature
describes
pathogenesis
NLRP3
describe
important
role
targeting
this
for
treatment
COVID-19.